Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10475-10489

  Duan, Hongliang ^a   Ning, Mengmeng ^a   Chen, Xiaoyan ^a   Zou, Qingan ^a   Zhang, Liming ^a   Feng, Ying ^a   Zhang, Lina ^a   Leng, Ying ^a   Shen, Jianhua ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

(4 PHENOXYPYRIDIN 3 YL)(4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; 4 PHENOXYNICOTINAMIDE DERIVATIVE; 4 PHENOXYPYRIMIDINE 5 CARBOXAMIDE DERIVATIVE; [4 (2 CHLOROPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,4,5 TRICHLOROPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,4,5 TRIMETHYLPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLORO 4 BROMOPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLORO 4 ETHYLPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLORO 4 METHYLPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](2,3 DIHYDRO 2H QUINOLIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](3,4 DIHYDRO 2H QUINOLIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](4 ALLYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](4 CYCLOBUTYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](4 ETHYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](4 ISOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DICHLOROPHENOXY)PYRIDIN 3 YL](4 PROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DIMETHOXYPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (2,5 DIMETHYLPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (3 CHLOROPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (3 METHOXYPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; [4 (4 METHYLPHENOXY)PYRIDIN 3 YL](4 CYCLOPROPYL 3,4 DIHYDRO 2H QUINOXALIN 1 YL)METHANONE; ANTIDIABETIC AGENT; ETHYL 4 (2 CHLOROPHENOXY)NICOTINATE; ETHYL 4 (2,5 DIMETHOXYPHENOXY)NICOTINATE; ETHYL 4 (2,5 DIMETHYLPHENOXY)NICOTINATE; ETHYL 4 (3 CHLOROPHENOXY)NICOTINATE; ETHYL 4 (3 METHOXYPHENOXY)NICOTINATE; ETHYL 4 (4 METHYLPHENOXY)NICOTINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GALLBLADDER; GLUCOSE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN SECRETION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED ICR; NIACINAMIDE; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84870976388     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301071h     Document Type: Article

References (34)

1. Porte, D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications Diabetes Metab. Res. Rev. 2001, 17, 181-188
2. Kikkawa, R. Chronic complications in diabetes mellitus Br. J. Nutr. 2000, 84, 183-185
3. International Diabetes Federation. Diabetes Atlas, 3 rd ed.; International Diabetes Federation: Brussels, Belgium, 2006.
4. Ripsin, C. M.; Kang, H.; Urban, R. J. Management of blood glucose in type 2 diabetes mellitus Am. Fam. Physician 2009, 79, 29-36
5. Libel, A.; Mata, M.; Eschwège, E. Evaluation of risk factors for development of complications in type II diabetes in Europe Diabetologia 2002, 45, S23-S28
6. Saydah, S. H.; Fradkin, J.; Cowie, C. C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes J. Am. Med. Assoc. 2004, 291, 335-342
7. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR) Biochem. Biophys. Res. Commun. 2002, 298, 714-719
8. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M. A G protein-coupled receptor responsive to bile acids J. Biol. Chem. 2003, 278, 9435-9440
9. Vassileva, G.; Golovko, A.; Markowitz, L.; Abbondanzo, S. J.; Zeng, M.; Yang, S.; Hoos, L.; Tetzloff, G.; Levitan, D.; Murgolo, N. J.; Keane, K.; Davis, H. R., Jr.; Hedrick, J.; Gustafson, E. L. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation Biochem. J. 2006, 398, 423-430
10. Watanabe, M.; Houten, S. M.; Mataki, C.; Christoffolete, M. A.; Kim, B. W.; Sato, H.; Messaddeq, N.; Harney, J. W.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A. C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 2006, 439, 484-489
11. Maruyama, T.; Tanaka, K.; Suzuki, J.; Miyoshi, H.; Harada, N.; Nakamura, T.; Miyamoto, Y.; Kanatani, A.; Tamai, Y. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice J. Endocrinol. 2006, 191, 197-205
12. Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1 Biochem. Biophys. Res. Commun. 2005, 329, 386-390
13. Stoffers, D.; Kieffer, T.; Hussain, M. A.; Drucker, D. J.; Bonner-Weir, S.; Habener, J.; Egan, J. Insulinotropic GLP-1 peptide agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes 2000, 49, 741-748
14. Wettergren, A.; Wojdemann, M.; Holst, J. J. The inhibitory effect of glucagon-like peptide-1 (7 36) amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9 36) amide Peptides 1998, 19, 877-882
15. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med. Chem. 2007, 50, 2297-2300
16. Pellicciari, R.; Gioiello, A.; Macchiarulo, A.; Thomas, C.; Rosatelli, E.; Natalini, B.; Sardella, R.; Pruzanski, M.; Roda, A.; Pastorini, E.; Schoonjans, K.; Auwerx, J. Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity J. Med. Chem. 2009, 52, 7958-7961
17. Budzik, B. W.; Evans, K. A.; Wisnoski, D. D.; Jin, J.; Rivero, R. A.; Szewczyk, G. R.; Jayawickreme, C.; Moncol, D. L.; Yu, H. Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists Bioorg. Med. Chem. Lett. 2010, 20, 1363-1367
18. Herbert, M. R.; Siegel, D. L.; Staszewski, L.; Cayanan, C.; Banerjee, U.; Dhamija, S.; Anderson, J.; Fan, A.; Wang, L.; Rix, P.; Shiau, A. K.; Rao, T. S.; Noble, S. A.; Heyman, R. A.; Bischoff, E.; Guha, M.; Kabakibi, A.; Pinkerton, A. B. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5 Bioorg. Med. Chem. Lett. 2010, 20, 5718-5721
19. Evans, K. A.; Budzik, B. W.; Ross, S. A.; Wisnoski, D. D.; Jin, J.; Rivero, R. A.; Vimal, M.; Szewczyk, G. R.; Jayawickreme, C.; Moncol, D. L.; Rimele, T. J.; Armour, S. L.; Weaver, S. P.; Griffin, R. J.; Tadepalli, S. M.; Jeune, M. R.; Shearer, T. W.; Chen, Z. B.; Chen, L.; Anderson, D. L.; Becherer, J. D.; De Los Frailes, M.; Colilla, F. J. Discovery of 3-aryl-4- isoxazolecarboxamides as TGR5 receptor agonists J. Med. Chem. 2009, 52, 7962-7965
20. Bissantz, C.; Dehmlow, H.; Martin, R. E.; Obst, S. U.; Richter, H.; Ullmer, C. Preparation of novel phenyl amide or pyridyl amide derivatives as GPBAR1 agonists for treating type II diabetes. US20100105906A1, 2010.
21. Maruyama, M. Therapeutic agent for irritable bowel syndrome containing TGR5 receptor agonists. WO2010016552A1, 2010.
22. Ellingson, R. C.; Henry, R. L. Pyrazine chemistry. IV. Bromination of 2-amino-3-carbomethoxypyrazine J. Am. Chem. Soc. 1949, 71, 2798-2800
23. Ulbricht, T. L. V.; Price, C. C. Some derivatives of malondialdehyde J. Org. Chem. 1957, 22, 235-238
24. Chen, W.; Cossrow, J.; Franklin, L.; Guan, B.; Jones, J. H.; Kumaravel, G.; Lane, B.; Littke, A.; Lugovskoy, A.; Peng, H.; Powell, N.; Raimundo, B.; Tanaka, H.; Vessels, J.; Wynn, T.; Xin, Z. Pyrimidine-4-carboxamide compounds useful as Raf kinase inhibitors and their preparation and use in the treatment of Raf-mediated diseases. WO2009006389A2, 2009.
25. Huang, T.-h.; Zhang, A.-d.; Deng, L.-f.; Tu, H.-y. Synthesis of ethyl 4-hydroxypyrimidine-5-carboxylate derivatives Huaxue Shiji 2009, 31, 541-542
26. Price, S.; Williams, K.; Savy, P. P.; Dyke, H. J.; Montana, J. G.; Stanley, M. S.; Bao, L. Preparation of azabenzofuranyl compounds as MEK kinase inhibitors. WO2008024725A1, 2008.
27. Woltering, E.; Tuch, A.; Dittrich-Wengenroth, E.; Kretschmer, A.; Baerfacker, L.; Bauser, M.; Ellinghaus, P.; Lustig, K.; Pook, E.; Weber, O. Preparation of 2-phenyl-5-pyrimidinecarboxylic acids as cardiovascular agents. WO2006097220A1, 2006.
28. Suzuki, R.; Mikami, A.; Tanaka, H.; Fukushima, H. Preparation of N -(adamantan-4-yl)-3,4-dihydroquinoline-1(2 H)-carboxamide and -3,4-dihydroquinoxaline-1(2 H)-carboxamide derivatives and related compounds as having 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitory activity. WO2009001817A1, 2008.
29. Herbert, J. M. Negishi-type coupling of bromoarenes with dimethylzinc Tetrahedron Lett. 2004, 45, 817-819
30. Li, T.; Holmstrom, S. R.; Kir, S.; Umetani, M.; Schmidt, D. R.; Kliewer, S. A.; Mangelsdorf, D. J. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling Mol. Endocrinol. 2011, 25, 1066-1071
31. Kerns, E. H.; Di, L. Metabolic stability. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization; Elsevier: London, UK, 2008; pp 149-150.
32. Perry, T. L.; Culling, C. F. A.; Berry, K.; Hansen, S. 7-Hydroxychlorpromazine: potential toxic drug metabolite in psychiatric patients Science 1964, 146, 81-83
33. Dayton, P. G.; Perel, J. M.; Cunningham, R. F.; Israili, Z. H.; Weiner, I. M. Studies of the fate of metabolites and analogs of probenecid Drug. Metab. Dispos. 1973, 1, 742-751
34. Kerns, E. H.; Di, L. Metabolic stability. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization; Elsevier: London, UK, 2008; pp 154-155.